Corealis Pharma, based in Laval, Quebec, has partnered with PhinC Group to enhance drug development processes through predictive modeling. This strategic collaboration aims to integrate physiologically based biopharmaceutics modeling (PBBM) and physiologically based pharmacokinetic (PBPK) modeling into the early formulation development of oral solid dosage forms. By using these advanced modeling techniques, the two organizations seek to improve the efficiency of the drug development pipeline and make more informed decisions earlier in the process, ultimately reducing the risks associated with clinical trials.
The integration of PBBM and PBPK modeling allows for a more thorough understanding of how a drug behaves in the body, which is critical for formulating effective medications. This development is particularly important in an industry that is constantly seeking to streamline processes and bring drugs to market more efficiently and safely. Both companies are optimistic that this collaboration will result in significant advancements within the pharmaceutical landscape, supporting better outcomes for drug development.
The collaboration highlights the growing trend within the pharmaceutical sector to leverage technology and data-driven approaches to enhance traditional methods of drug development. As the industry evolves, partnerships like this may play a critical role in shaping the future of medication formulation and delivery.
Analyzed Canadian Outlets (1)
1 headline